预约演示
Fierce Biotech Fundraising Tracker '24: HI-Bio secures $95M; Radionetics raises $52.5M
Welcome to the 2024 fundraising tracker (Fierce Biotech's version).
A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024.
We're bumping up our reporting criteria from last year's tracker, including any fundraising rounds north of $50 million this time around. We'll still profile exciting new companies and larger rounds in-depth, while we focus more coverage on clinical trial results, special reports and enterprise stories.
January
Jan. 4—Claris Bio
Series:Claris Bio
Amount: $57 million
Investors: Novo Holdings A/S, RA Capital, Mass General Brigham Ventures and Janus Henderson Investors
A new bioteNovo Holdings A/Sth $57 millionMass GeneraltBrigham VenturesseaseJanus Hendersonoke stealth cover Thursday, led by Clarke Atwell. The company, initially funded in 2020, is developing CSB-001 as a topical ocular biologic solution to restore structural and functional corneal integrity to eyes with neurotrophic keratopathy. Release
Jan. 4—Moonwalk Biosciencescorneal diseaseClaris BioCSB-001neurotrophic keratopathy
Series:Moonwalk Biosciences
Amount: $57 million
Investors: Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures and YK Bioventures
The Broad Institute of MIT and Harvard's CRISPR gene edFuture Venturesng ZhaKhosla Ventureshe scYK Bioventuresr of Moonwalk Therapeutics, which emerged today with $57 million to develop new epigenetic medicines. The company's epigenetic profiling and engineering technology platform targets the epigentic code, called the software of the genome. Release
Jan. 4—Human Immunology BioscieHarvardI-Bio)Moonwalk Therapeutics
Amount: $95 million
Investors: Alpha Wave Global, Viking Global Investors, Arkin Bio Capital, Jeito Capital and ARCH Venture Partners.
HI-Bio has secured $95 millionViking GlobalB round, monArkin Bio CapitalunJeito Capitalfelzartamab, the biotech's lead therapeutic candidate. The clinical-stage monoclonal antibody targets CD38 and was in-licensed from MorphoSys. HI-Bio is assessing felzartamab in antibody-mediated rejection, IgA nephropathy, lupus nephritis and primary membranous nephropathy. The biotech will also direct the new money toward a clinical study for HIB210, an anti-C5aR1 candidate targeting neutrophil activation and chemotaxis. Release
Series: A
Amount: $52.5 million
Investors: Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals and GordonMD Global Investments.
Radionetics has raised a $52.5 million series A,DCVC Biog Crinetics Pharmaceuticals total raised to $82.5 million. The young biotech plans to use the new funds to build out a pipeline of small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) to treat a range of cancers. In tandem with the financing, the company has also tapped Paul Grayson to take on the top spot as CEO. With more than 25 years of industry experience under his belt, Grayson most recently served as president and CEO of Tentarix Biotherapeutics. Release
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。